Eya Rahmouni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eya Rahmouni has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Tarek Ben Dhiab
Department of Surgical Oncology, Salah Azaiez Institute, Tunis, Tunisia
5 shared publicationsGhada Sahraoui
Department of Anatomopathology, Salah Azaiez Institute, Tunis, Tunisia
2 shared publicationsHouyem Mansouri
Department of surgical oncology, Regional Hospital of Jendouba, Tunisia
2 shared publicationsLeila Achouri
Department of surgical oncology, Regional Hospital of Jendouba, Tunisia
2 shared publicationsRacha Ben Romdhane
Department of surgical oncology, Regional Hospital of Jendouba, Tunisia
2 shared publicationsSabrine Boukhris
Department of surgical oncology, Regional Hospital of Jendouba, Tunisia
2 shared publications
Latest Publications
- Open Access
- 12 September 2026
- Published by SAGE Publications in Women's Health
- Vol. 22
Ovarian metastasis from neuroendocrine tumor presenting as hot flashes: A case report and literature review
Neuroendocrine metastases to the ovaries are extremely rare, with approximately 100 cases reported in the English literature. The most frequent primary source is a small bowel neuroendocrine tumor (NET), particularly of ileal origin, and patients often present with widespread metastases and carcinoid syndrome. We report the case of a 46-year-old North African woman who presented with hot flashes, motility diarrhea, and a cutaneous rash of the neckline persisting for 3 months, initially misattributed to perimenopause. Imaging revealed bilateral ovarian masses classified as ORADS 4. Surgical exploration found bilateral adnexal tumors and multiple peritoneal nodules; a total hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and nodule resection were performed. Histology revealed bilateral ovarian involvement by a well-differentiated NET, also affecting peritoneal nodules. The primary origin was unclear, prompting comprehensive staging, including an octreoscan, computed tomography scan, and enteric magnetic resonance imaging, which revealed retractile mesenteritis and a 4-cm mass involving the cecum and terminal ileum, along with mesenteric lymphadenopathy. A right hemicolectomy with resection of 1 m of small bowel and mesenteric nodes confirmed a well-differentiated NET of the cecum and ileum with negative surgical margins. The patient was started on long-acting repeatable octreotide. This case underlines the importance of considering a neuroendocrine origin in perimenopausal women presenting with symptoms suggestive of carcinoid syndrome, as these may be mistaken for menopausal changes.
- 12 September 2026
- Published by SAGE Publications in Women's Health
- Vol. 22
Open AccessOvarian metastasis from neuroendocrine tumor presenting as hot flashes: A case report and literature review
Neuroendocrine metastases to the ovaries are extremely rare, with approximately 100 cases reported in the English literature. The most frequent primary source is a small bowel neuroendocrine tumor (NET), particularly of ileal origin, and patients often present with widespread metastases and carcinoid syndrome. We report the case of a 46-year-old North African woman who presented with hot flashes, motility diarrhea, and a cutaneous rash of the neckline persisting for 3 months, initially misattributed to perimenopause. Imaging revealed bilateral ovarian masses classified as ORADS 4. Surgical exploration found bilateral adnexal tumors and multiple peritoneal nodules; a total hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and nodule resection were performed. Histology revealed bilateral ovarian involvement by a well-differentiated NET, also affecting peritoneal nodules. The primary origin was unclear, prompting comprehensive staging, including an octreoscan, computed tomography scan, and enteric magnetic resonance imaging, which revealed retractile mesenteritis and a 4-cm mass involving the cecum and terminal ileum, along with mesenteric lymphadenopathy. A right hemicolectomy with resection of 1 m of small bowel and mesenteric nodes confirmed a well-differentiated NET of the cecum and ileum with negative surgical margins. The patient was started on long-acting repeatable octreotide. This case underlines the importance of considering a neuroendocrine origin in perimenopausal women presenting with symptoms suggestive of carcinoid syndrome, as these may be mistaken for menopausal changes.
- Open Access
- 22 May 2026
- Published by SAGE Publications in Women's Health
- Vol. 22
Duodenal metastasis from endometrial cancer: A rare metastatic site, a case report and literature review
Duodenal metastasis from endometrial cancer is exceedingly rare, with only seven cases reported in the literature. While endometrial cancer typically spreads to lymph nodes, lungs, and the peritoneum, gastrointestinal involvement, particularly in the duodenum, is an uncommon and diagnostically challenging occurrence. We report the case of a 49-year-old woman initially treated for a stage IIIC2, grade 2 endometrioid adenocarcinoma via total hysterectomy, lymphadenectomy, and adjuvant radiochemotherapy. After 1 year of complete remission, she presented with epigastric pain and hematuria. Imaging revealed circumferential thickening of the third portion of the duodenum, complicated by a rare duodenopyelic fistula and right renal obstruction. Endoscopic biopsy confirmed a poorly differentiated carcinoma of endometrial origin. Palliative management involved duodenal stenting, ureteral JJ stent placement, and systemic chemotherapy. This case highlights that duodenal metastasis from endometrial adenocarcinoma is often diagnosed late and carries a poor prognosis, necessitating a multimodal palliative approach aimed at symptom control.
- 22 May 2026
- Published by SAGE Publications in Women's Health
- Vol. 22
Open AccessDuodenal metastasis from endometrial cancer: A rare metastatic site, a case report and literature review
Duodenal metastasis from endometrial cancer is exceedingly rare, with only seven cases reported in the literature. While endometrial cancer typically spreads to lymph nodes, lungs, and the peritoneum, gastrointestinal involvement, particularly in the duodenum, is an uncommon and diagnostically challenging occurrence. We report the case of a 49-year-old woman initially treated for a stage IIIC2, grade 2 endometrioid adenocarcinoma via total hysterectomy, lymphadenectomy, and adjuvant radiochemotherapy. After 1 year of complete remission, she presented with epigastric pain and hematuria. Imaging revealed circumferential thickening of the third portion of the duodenum, complicated by a rare duodenopyelic fistula and right renal obstruction. Endoscopic biopsy confirmed a poorly differentiated carcinoma of endometrial origin. Palliative management involved duodenal stenting, ureteral JJ stent placement, and systemic chemotherapy. This case highlights that duodenal metastasis from endometrial adenocarcinoma is often diagnosed late and carries a poor prognosis, necessitating a multimodal palliative approach aimed at symptom control.
- Open Access
- 1 August 2025
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 133 (C) , 111565
Sertoli-Leydig cell tumor: An unusual pathological presentation raising a therapeutic dilemma, a case report
Introduction: Sertoli–Leydig cell tumors (SLCTs) are rare, with a challenging diagnosis and management. Herein is our case. Case report: We report the case of a 14-year-old female patient who presented with secondary amenorrhea with clinical signs of virilization. A pelvic MRI showed a solid-cystic intraperitoneal mass. The patient underwent surgery. A left adnexectomy, along with an omentectomy, peritoneal biopsy, and peritoneal cytology sampling, was performed. The histopathological examination confirmed a Sertoli-Leydig cell tumor of the left ovary. While the majority of the tumor cells were well-differentiated, a focal area contained poorly differentiated cells with high mitotic activity and sarcoma-like features. The case was presented at a multidisciplinary tumor board meeting to assess the potential benefit of adjuvant chemotherapy, given the presence of a poorly differentiated component. However, adjuvant chemotherapy was not recommended. Discussion: SLCTs are rare ovarian neoplasms that predominantly affect individuals of reproductive age. Virilization occurs in up to 60 % of cases. Serum tumor markers can aid in the detection of SLCTs. According to the latest WHO classification, SLCTs are categorized as well-differentiated, moderately differentiated, or poorly differentiated. Surgical resection remains the gold standard treatment, while postoperative chemotherapy is recommended for patients with poor prognostic factors. However, managing SLCTs remains challenging due to the lack of standardized treatment guidelines. Prognosis is primarily determined by tumor stage and degree of differentiation. Conclusion: Managing SLCTs remains complex, and further studies are needed to better define treatment guidelines. Highlights:
- 1 August 2025
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 133 (C) , 111565
Open AccessSertoli-Leydig cell tumor: An unusual pathological presentation raising a therapeutic dilemma, a case report
Introduction: Sertoli–Leydig cell tumors (SLCTs) are rare, with a challenging diagnosis and management. Herein is our case. Case report: We report the case of a 14-year-old female patient who presented with secondary amenorrhea with clinical signs of virilization. A pelvic MRI showed a solid-cystic intraperitoneal mass. The patient underwent surgery. A left adnexectomy, along with an omentectomy, peritoneal biopsy, and peritoneal cytology sampling, was performed. The histopathological examination confirmed a Sertoli-Leydig cell tumor of the left ovary. While the majority of the tumor cells were well-differentiated, a focal area contained poorly differentiated cells with high mitotic activity and sarcoma-like features. The case was presented at a multidisciplinary tumor board meeting to assess the potential benefit of adjuvant chemotherapy, given the presence of a poorly differentiated component. However, adjuvant chemotherapy was not recommended. Discussion: SLCTs are rare ovarian neoplasms that predominantly affect individuals of reproductive age. Virilization occurs in up to 60 % of cases. Serum tumor markers can aid in the detection of SLCTs. According to the latest WHO classification, SLCTs are categorized as well-differentiated, moderately differentiated, or poorly differentiated. Surgical resection remains the gold standard treatment, while postoperative chemotherapy is recommended for patients with poor prognostic factors. However, managing SLCTs remains challenging due to the lack of standardized treatment guidelines. Prognosis is primarily determined by tumor stage and degree of differentiation. Conclusion: Managing SLCTs remains complex, and further studies are needed to better define treatment guidelines. Highlights:
- Open Access
- 5 June 2025
- Published by SAGE Publications in Women's Health
- Vol. 21
Ovarian carcinoma and peritoneal tuberculosis: A rare coexistence with challenging diagnosis, a case report and literature review
Peritoneal tuberculosis is one of the most challenging forms of extrapulmonary tuberculosis to diagnose, especially, in women as it often mimics an advanced ovarian carcinoma. Many authors had documented cases where peritoneal tuberculosis was initially misdiagnosed as advanced ovarian carcinoma, but only four cases had reported the coexistence of both conditions. We present the fifth case in the literature of concurrent peritoneal tuberculosis and serous cystadenocarcinoma of the ovary. A 61-year-old female patient presented with diffuse abdominal tenderness. Physical examination revealed an abdominal distension. Computed tomography scan showed a heterogeneous, poorly defined right latero-uterine mass associated with ascites and nodular peritoneal infiltration. The level of cancer antigen 125 was elevated. Therefore, a diagnosis of advanced ovarian carcinoma was highly suspected. A diagnostic laparoscopy was performed. Peritoneal biopsy confirmed the diagnosis of peritoneal tuberculosis without any histological evidence of malignancy. The patient subsequently underwent a right adnexectomy, which revealed serous cystadenocarcinoma of the ovary. She received 6 months of antituberculosis treatment complicated with renal dysfunction. Computed tomography scan control showed no abnormalities. Tumor markers levels decreased to the normal range. The patient refused further surgery and chemotherapy was recommended. Female patients presenting with ascites, adnexal masses, and elevated levels of cancer antigen 125 are usually presumed to have advanced ovarian carcinoma. There are a few discriminating features that suggest the diagnosis of peritoneal tuberculosis rather than peritoneal carcinomatosis of an advanced ovarian carcinoma. Eventually, their coexistence should be considered as a differential diagnosis, particularly in developing countries where tuberculosis is still endemic as it is the case of Tunisia.
- 5 June 2025
- Published by SAGE Publications in Women's Health
- Vol. 21
Open AccessOvarian carcinoma and peritoneal tuberculosis: A rare coexistence with challenging diagnosis, a case report and literature review
Peritoneal tuberculosis is one of the most challenging forms of extrapulmonary tuberculosis to diagnose, especially, in women as it often mimics an advanced ovarian carcinoma. Many authors had documented cases where peritoneal tuberculosis was initially misdiagnosed as advanced ovarian carcinoma, but only four cases had reported the coexistence of both conditions. We present the fifth case in the literature of concurrent peritoneal tuberculosis and serous cystadenocarcinoma of the ovary. A 61-year-old female patient presented with diffuse abdominal tenderness. Physical examination revealed an abdominal distension. Computed tomography scan showed a heterogeneous, poorly defined right latero-uterine mass associated with ascites and nodular peritoneal infiltration. The level of cancer antigen 125 was elevated. Therefore, a diagnosis of advanced ovarian carcinoma was highly suspected. A diagnostic laparoscopy was performed. Peritoneal biopsy confirmed the diagnosis of peritoneal tuberculosis without any histological evidence of malignancy. The patient subsequently underwent a right adnexectomy, which revealed serous cystadenocarcinoma of the ovary. She received 6 months of antituberculosis treatment complicated with renal dysfunction. Computed tomography scan control showed no abnormalities. Tumor markers levels decreased to the normal range. The patient refused further surgery and chemotherapy was recommended. Female patients presenting with ascites, adnexal masses, and elevated levels of cancer antigen 125 are usually presumed to have advanced ovarian carcinoma. There are a few discriminating features that suggest the diagnosis of peritoneal tuberculosis rather than peritoneal carcinomatosis of an advanced ovarian carcinoma. Eventually, their coexistence should be considered as a differential diagnosis, particularly in developing countries where tuberculosis is still endemic as it is the case of Tunisia.
- Open Access
- 1 June 2025
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 131 (C) , 111416
Gastric squamous cell carcinoma: Is neoadjuvant chemotherapy always effective? A case report
Introduction: Gastric squamous cell carcinoma (GSCC) is a rare condition. We present the case of a locally advanced GSCC with dissociated response after neoadjuvant chemotherapy. Case report: We present the case of a 34-year-old female patient who presented with a two-month history of epigastric pain and vomiting. Esophagogastroduodenoscopy identified a fundic lesion. Biopsy revealed a GSCC. CT scan showed a locally advanced expansile nodular process on the greater curvature of the stomach. Due to the locally advanced nature of the tumor, surgery was deemed excessively mutilating, and chemotherapy was initiated. The endoscopic evaluation showed complete resolution of the fundic mass. CT imaging demonstrated a 37 % reduction in the volume of target lesions. The patient subsequently underwent diagnostic laparoscopy, revealing a locally advanced unresectable tumor accompanied by diffuse peritoneal carcinomatosis. Palliative chemotherapy was initiated. The patient passed away two months after surgery. Discussion: GSCC is a rare condition. The exact origin of this tumor remains unclear. Clinically, GSCC presents similarly to other gastric tumors. Due to its rarity, there is no consensus on the optimal treatment for primary gastric squamous cell carcinoma, and the existing evidence is primarily based on case reports and small case series. Radical surgical excision with lymph node dissection remains the primary therapeutic approach. While neoadjuvant chemotherapy appears beneficial and effective, the available data remain limited. GSCC is known for its locally aggressive behavior and poor short-term prognosis. Conclusion: Additional research is crucial to establish the most effective treatment strategies. Highlights:
- 1 June 2025
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 131 (C) , 111416
Open AccessGastric squamous cell carcinoma: Is neoadjuvant chemotherapy always effective? A case report
Introduction: Gastric squamous cell carcinoma (GSCC) is a rare condition. We present the case of a locally advanced GSCC with dissociated response after neoadjuvant chemotherapy. Case report: We present the case of a 34-year-old female patient who presented with a two-month history of epigastric pain and vomiting. Esophagogastroduodenoscopy identified a fundic lesion. Biopsy revealed a GSCC. CT scan showed a locally advanced expansile nodular process on the greater curvature of the stomach. Due to the locally advanced nature of the tumor, surgery was deemed excessively mutilating, and chemotherapy was initiated. The endoscopic evaluation showed complete resolution of the fundic mass. CT imaging demonstrated a 37 % reduction in the volume of target lesions. The patient subsequently underwent diagnostic laparoscopy, revealing a locally advanced unresectable tumor accompanied by diffuse peritoneal carcinomatosis. Palliative chemotherapy was initiated. The patient passed away two months after surgery. Discussion: GSCC is a rare condition. The exact origin of this tumor remains unclear. Clinically, GSCC presents similarly to other gastric tumors. Due to its rarity, there is no consensus on the optimal treatment for primary gastric squamous cell carcinoma, and the existing evidence is primarily based on case reports and small case series. Radical surgical excision with lymph node dissection remains the primary therapeutic approach. While neoadjuvant chemotherapy appears beneficial and effective, the available data remain limited. GSCC is known for its locally aggressive behavior and poor short-term prognosis. Conclusion: Additional research is crucial to establish the most effective treatment strategies. Highlights:
- Open Access
- 1 January 2025
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 126 (C) , 110762
Rosai-Dorfman disease: A rare presentation as an isolated axillary lymphadenopathy, a case report and literature review
Introduction: Rosai-Dorfman disease (RDD) is a rare histiocytic neoplasm. It most commonly presents with bilateral cervical lymphadenopathy. We report the fourth case in the literature of RDD presenting as isolated axillary lymphadenopathy. Case report: We report the case of a 55-year-old female patient who presented with right axillary lymphadenopathy that had persisted for 1 year, without other associated symptoms. Physical examination revealed an isolated right axillary lymphadenopathy. An excisional biopsy of the lymph node was performed, and histopathological findings were consistent with Rosai-Dorfman's disease. Regular follow-up was recommended. Discussion: RDD is an uncommon histiocytic disorder. Initially identified in the 1960s as a benign, self-limited condition, RDD is now classified as a neoplastic disorder with causative mutations in the MAPK pathway. The classic presentation involves extensive, painless bilateral cervical lymphadenopathy. Isolated axillary lymph node involvement, as seen in our patient, is a rare presentation of nodal RDD with only three cases reported in the literature to date. Histologically, RDD is characterized by a prominent histiocytic infiltrate set against a background of inflammatory cells, primarily composed of lymphocytes and plasma cells. These histiocytes are typically hypochromatic, with abundant pale cytoplasm, and exhibit varying degrees of emperipolesis. In 2018, consensus guidelines for the management and evaluation of RDD were introduced. Conclusion: Recent advances in genetic sequencing have reclassified RDD from a benign inflammatory disorder to a histiocytic neoplasm. Further research is needed to fully understand its implications for prognosis and treatment strategies. Highlights:
- 1 January 2025
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 126 (C) , 110762
Open AccessRosai-Dorfman disease: A rare presentation as an isolated axillary lymphadenopathy, a case report and literature review
Introduction: Rosai-Dorfman disease (RDD) is a rare histiocytic neoplasm. It most commonly presents with bilateral cervical lymphadenopathy. We report the fourth case in the literature of RDD presenting as isolated axillary lymphadenopathy. Case report: We report the case of a 55-year-old female patient who presented with right axillary lymphadenopathy that had persisted for 1 year, without other associated symptoms. Physical examination revealed an isolated right axillary lymphadenopathy. An excisional biopsy of the lymph node was performed, and histopathological findings were consistent with Rosai-Dorfman's disease. Regular follow-up was recommended. Discussion: RDD is an uncommon histiocytic disorder. Initially identified in the 1960s as a benign, self-limited condition, RDD is now classified as a neoplastic disorder with causative mutations in the MAPK pathway. The classic presentation involves extensive, painless bilateral cervical lymphadenopathy. Isolated axillary lymph node involvement, as seen in our patient, is a rare presentation of nodal RDD with only three cases reported in the literature to date. Histologically, RDD is characterized by a prominent histiocytic infiltrate set against a background of inflammatory cells, primarily composed of lymphocytes and plasma cells. These histiocytes are typically hypochromatic, with abundant pale cytoplasm, and exhibit varying degrees of emperipolesis. In 2018, consensus guidelines for the management and evaluation of RDD were introduced. Conclusion: Recent advances in genetic sequencing have reclassified RDD from a benign inflammatory disorder to a histiocytic neoplasm. Further research is needed to fully understand its implications for prognosis and treatment strategies. Highlights:
- Open Access
- 1 December 2024
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 125 (C) , 110569
Metatypical basal cell carcinoma: A successful balance between oncologic outcome and aesthetic result, a case report
Introduction: Metatypical basal cell carcinoma is a rare and aggressive subtype of skin cancer. It necessitates a careful and nuanced approach to management. The first-line treatment is a wide surgical excision, which can lead to significant tissue loss. Herein is our case. Case report: A 67-year-old female patient presented with an ulcerated exophytic mass on the right parietal scalp. She underwent a large excision of the tumor, sentinel lymph node biopsy, and reconstruction with a transposition flap. Histopathological examination revealed a metatypical basal cell carcinoma with minimal clear surgical margins of 1 cm; lymph nodes were negative. Adjuvant radiotherapy was recommended. Discussion: Metatypical basal cell carcinoma is a rare and aggressive subtype of non-melanoma skin cancer, accounting for about 2 % of all cases. It has a higher risk of metastasis and recurrence compared to typical basal cell carcinoma. Metatypical basal cell carcinoma most often develops in sun-exposed areas of the head, although it can occur in other locations less frequently. Despite the absence of established treatment guidelines, it is recommended to use wider surgical margins than those typically applied for basal cell carcinoma. This approach often leads to substantial tissue loss, which may necessitate challenging reconstructive procedures. Ongoing research is crucial as we navigate the complexities of managing metatypical basal cell carcinoma, particularly concerning surgical margin cutoffs, lymph node staging, and adjuvant therapies. Conclusion: Due to its rarity, metatypical basal cell carcinoma presents ongoing challenges with no consensual management strategies. Highlights:
- 1 December 2024
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 125 (C) , 110569
Open AccessMetatypical basal cell carcinoma: A successful balance between oncologic outcome and aesthetic result, a case report
Introduction: Metatypical basal cell carcinoma is a rare and aggressive subtype of skin cancer. It necessitates a careful and nuanced approach to management. The first-line treatment is a wide surgical excision, which can lead to significant tissue loss. Herein is our case. Case report: A 67-year-old female patient presented with an ulcerated exophytic mass on the right parietal scalp. She underwent a large excision of the tumor, sentinel lymph node biopsy, and reconstruction with a transposition flap. Histopathological examination revealed a metatypical basal cell carcinoma with minimal clear surgical margins of 1 cm; lymph nodes were negative. Adjuvant radiotherapy was recommended. Discussion: Metatypical basal cell carcinoma is a rare and aggressive subtype of non-melanoma skin cancer, accounting for about 2 % of all cases. It has a higher risk of metastasis and recurrence compared to typical basal cell carcinoma. Metatypical basal cell carcinoma most often develops in sun-exposed areas of the head, although it can occur in other locations less frequently. Despite the absence of established treatment guidelines, it is recommended to use wider surgical margins than those typically applied for basal cell carcinoma. This approach often leads to substantial tissue loss, which may necessitate challenging reconstructive procedures. Ongoing research is crucial as we navigate the complexities of managing metatypical basal cell carcinoma, particularly concerning surgical margin cutoffs, lymph node staging, and adjuvant therapies. Conclusion: Due to its rarity, metatypical basal cell carcinoma presents ongoing challenges with no consensual management strategies. Highlights: